JP2024012421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024012421A5 JP2024012421A5 JP2023185401A JP2023185401A JP2024012421A5 JP 2024012421 A5 JP2024012421 A5 JP 2024012421A5 JP 2023185401 A JP2023185401 A JP 2023185401A JP 2023185401 A JP2023185401 A JP 2023185401A JP 2024012421 A5 JP2024012421 A5 JP 2024012421A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- clostridial neurotoxin
- bont
- activation loop
- modified clostridial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1815817.0 | 2018-09-28 | ||
| GBGB1815817.0A GB201815817D0 (en) | 2018-09-28 | 2018-09-28 | Clostridial neurotoxins comprising and exogenous activation loop |
| JP2021517796A JP7511549B2 (ja) | 2018-09-28 | 2019-09-27 | 外因性活性化ループを含むクロストリジウム神経毒 |
| PCT/GB2019/052732 WO2020065336A1 (en) | 2018-09-28 | 2019-09-27 | Clostridial neurotoxins comprising an exogenous activation loop |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517796A Division JP7511549B2 (ja) | 2018-09-28 | 2019-09-27 | 外因性活性化ループを含むクロストリジウム神経毒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024012421A JP2024012421A (ja) | 2024-01-30 |
| JP2024012421A5 true JP2024012421A5 (https=) | 2024-09-17 |
| JP7819168B2 JP7819168B2 (ja) | 2026-02-24 |
Family
ID=64108972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517796A Active JP7511549B2 (ja) | 2018-09-28 | 2019-09-27 | 外因性活性化ループを含むクロストリジウム神経毒 |
| JP2023185401A Active JP7819168B2 (ja) | 2018-09-28 | 2023-10-30 | 外因性活性化ループを含むクロストリジウム神経毒 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517796A Active JP7511549B2 (ja) | 2018-09-28 | 2019-09-27 | 外因性活性化ループを含むクロストリジウム神経毒 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12589139B2 (https=) |
| EP (1) | EP3856232A1 (https=) |
| JP (2) | JP7511549B2 (https=) |
| KR (1) | KR20210068476A (https=) |
| CN (1) | CN113164565A (https=) |
| AU (1) | AU2019348732C1 (https=) |
| BR (1) | BR112021005017A2 (https=) |
| CA (1) | CA3111962A1 (https=) |
| EA (1) | EA202190889A1 (https=) |
| GB (1) | GB201815817D0 (https=) |
| IL (1) | IL281814A (https=) |
| MX (1) | MX2021003261A (https=) |
| SG (1) | SG11202102323TA (https=) |
| TW (2) | TW202517790A (https=) |
| UA (1) | UA130362C2 (https=) |
| WO (1) | WO2020065336A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| WO2022208091A1 (en) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| JP7659653B2 (ja) | 2021-03-30 | 2025-04-09 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| CN115785237B (zh) * | 2022-09-01 | 2023-06-16 | 上海蓝晶生物科技有限公司 | 一种重组肉毒杆菌毒素及其制备方法 |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) * | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| CN116813727B (zh) * | 2023-06-08 | 2025-06-06 | 苏州德进生物制药有限公司 | 一种a型肉毒毒素的制备方法及其应用 |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| CN118126143B (zh) * | 2024-03-14 | 2025-06-24 | 河北平朴生物科技合伙企业(有限合伙) | 一种a型肉毒毒素的突变体及其应用 |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
| CN119859174B (zh) * | 2025-01-13 | 2026-03-20 | 乐普健糖药业(重庆)有限公司 | 重组肉毒毒素及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| DK1084146T3 (da) | 1998-05-13 | 2003-02-03 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf |
| ES2205849T3 (es) | 1998-07-22 | 2004-05-01 | Osprey Pharmaceuticals Limited | Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares. |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| WO2000039310A1 (en) * | 1998-12-29 | 2000-07-06 | The University Of Georgia Research Foundation, Inc. | Rubredoxin fusion proteins, protein expression system and methods |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| HK1046020B (en) | 1999-08-25 | 2007-05-11 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| PL1830872T3 (pl) | 2004-12-01 | 2011-09-30 | Sec Dep For Health | Białka fuzyjne |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| EP1931379B1 (en) * | 2005-10-07 | 2013-05-29 | Health Protection Agency | Proteins with improved solubility and methods for producing and using same |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP2009543558A (ja) | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| JP5799397B2 (ja) * | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ | 癌の抑制 |
| GB0815264D0 (en) | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
| KR20110106346A (ko) | 2008-12-10 | 2011-09-28 | 알러간, 인코포레이티드 | 클로스트리디움 독소 약제학적 조성물 |
| GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| CA2758274C (en) | 2009-04-14 | 2018-04-10 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| CZ2010374A3 (cs) * | 2010-05-13 | 2011-06-29 | Zentiva, K.S. | Rekombinantní produkce teriparatidu v bakteriích Escherichia coli |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| WO2013091895A1 (en) | 2011-12-23 | 2013-06-27 | Merz Pharma Gmbh & Co. Kgaa | Novel method for the manufacturing of di-chain proteins for use in humans |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| CN107108703B (zh) * | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| US11242515B2 (en) | 2016-05-16 | 2022-02-08 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| WO2019152380A1 (en) | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
-
2018
- 2018-09-28 GB GBGB1815817.0A patent/GB201815817D0/en not_active Ceased
-
2019
- 2019-09-27 UA UAA202102226A patent/UA130362C2/uk unknown
- 2019-09-27 SG SG11202102323TA patent/SG11202102323TA/en unknown
- 2019-09-27 EP EP19782680.3A patent/EP3856232A1/en active Pending
- 2019-09-27 BR BR112021005017-5A patent/BR112021005017A2/pt unknown
- 2019-09-27 WO PCT/GB2019/052732 patent/WO2020065336A1/en not_active Ceased
- 2019-09-27 KR KR1020217012010A patent/KR20210068476A/ko not_active Ceased
- 2019-09-27 AU AU2019348732A patent/AU2019348732C1/en active Active
- 2019-09-27 TW TW113126928A patent/TW202517790A/zh unknown
- 2019-09-27 CN CN201980078275.8A patent/CN113164565A/zh active Pending
- 2019-09-27 JP JP2021517796A patent/JP7511549B2/ja active Active
- 2019-09-27 MX MX2021003261A patent/MX2021003261A/es unknown
- 2019-09-27 TW TW108135053A patent/TWI869353B/zh active
- 2019-09-27 US US17/278,724 patent/US12589139B2/en active Active
- 2019-09-27 EA EA202190889A patent/EA202190889A1/ru unknown
- 2019-09-27 CA CA3111962A patent/CA3111962A1/en active Pending
-
2021
- 2021-03-25 IL IL281814A patent/IL281814A/en unknown
-
2023
- 2023-10-30 JP JP2023185401A patent/JP7819168B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024012421A5 (https=) | ||
| JP2022046597A5 (https=) | ||
| US12589139B2 (en) | Clostridial neurotoxins comprising an exogenous activation loop | |
| CA2799969C (en) | Degradable clostridial toxins | |
| JP2019528042A5 (https=) | ||
| JP2015519362A5 (https=) | ||
| FI3481852T3 (fi) | Uusi botulinum-neurotoksiini ja sen johdannaisia | |
| JP2019523015A5 (https=) | ||
| EP4289868A1 (en) | Modified neurotoxin single-chain polypeptide and use thereof | |
| JP2005517627A5 (https=) | ||
| CA2703364A1 (en) | Methods of treating chronic neurogenic inflammation using modified clostridial toxins | |
| US20100303757A1 (en) | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases | |
| JP2016513082A5 (https=) | ||
| US20190161783A1 (en) | Production of activated clostridial neurotoxins | |
| TH2101001791A (th) | คลอสทริเดียลนิวโรทอกซินซึ่งประกอบรวมด้วยลูปการกระตุ้นแบบเอ็กโซจีเนียส | |
| RU2023125554A (ru) | Клостридиальные нейротоксины, содержащие экзогенную петлю активации | |
| RU2025110789A (ru) | Клостридиальные нейротоксины, содержащие активирующий сайт расщепления эндосомальной протеазой | |
| US20240175001A1 (en) | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | |
| EP4594341A1 (en) | Clostridial neurotoxins comprising an activating exogenous protease cleavage site | |
| JP2023090955A5 (https=) | ||
| RU2019108257A (ru) | Сконструированный ботулинический нейротоксин | |
| Fernandez-Salas et al. | Steward et al. | |
| NZ747619B2 (en) | Chimeric neurotoxins | |
| RU2021111910A (ru) | Терапевтическое и косметическое применение нейротоксина ботулина серотипа e | |
| NZ747619A (en) | Chimeric neurotoxins |